Trial | NCT02622022  Report issue

Official Title

Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    morphine ...

  • Study Participants

    36
36 patients with interstitial lung disease will be randomized to 1 weeks treatment with morphine hydrochloride as oral linctus 5 mg, four times a day, and 5 mg as needed up to 4 times a day, or corresponding doses of placebo.

VAS score for dyspnea will be evaluated after 1 hour and 1 week at follow up. Other questionnaires will also be evaluated (GAD-7, K-BUILD, Leicester score)
Study Started
Jan 31
2016
Primary Completion
Feb 06
2019
Study Completion
Feb 06
2019
Last Update
Apr 10
2019

Drug Morphine hydrochloride

  • Other names: Placebo

Other Placebo

Morphine Active Comparator

18 patients treated with oral morphine hydrochloride linctus 5 mg 4 four times daily and as needed up to 4 times daily

Placebo Placebo Comparator

18 patients treated with oral linctus corresponding to 5 mg morphine hydrochloride, four times daily and as needed up to 4 times daily

Criteria 

Inclusion Criteria:

A diagnosis of interstitial lung disease (IPF, NSIP, RA-ILS, Scl-ILS, MCTD-ILS, asbestous, drug induced ILD, unclassified ILD)
Dyspnea corresponding to Medial Research Councils (MRC) dyspnea score ≥ 3
Written consent
Age ≥ 18 years
Competent
For fertile women: Negative pregnancy test
For fertile and sexually active participants: Use of safe anti-conceptionals

Exclusion Criteria:

Ongoing infection
Decreased lung function to a degree which makes any form of respiratory depression life threatening
Treatment with morphine or morphine analogues
Allergy towards morphine hydrochloride
No Results Posted